Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis [UC] or Crohn's disease [CD] has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 [C average ] as exposure measure. Results: Higher vedolizumab concentrations were associated with higher clinical remission rates; the exposure-efficacy relationship was steeper for UC than CD. Unadjusted analyses overestimated the relationship, more so for CD. From covariate-adjusted models, average probability of remission at Week 6 increased by approximately 15% for UC and 10% for CD between C average values of 35 and 84 µg/ml [5th and 95th percentiles, respectively]. On average, patients with higher albumin, lower faecal calprotectin [UC only], lower C-reactive protein [CD only], and no previous tumour necrosis factor-α [TNFα] antagonist use had a higher remission probability. Previous TNFα antagonist use had the greatest impact; remission probability was approximately 10% higher in treatment-naïve patients.
Introduction
Vedolizumab, a humanised immunoglobulin G 1 monoclonal antibody that binds exclusively to the lymphocyte integrin α 4 β 7 , is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis [UC] or Crohn's disease [CD] . The mechanism of action of vedolizumab differs from that of other marketed biologics for the treatment of inflammatory bowel disease [IBD] , including natalizumab and tumour necrosis factor-α [TNFα] antagonists. By binding specifically to α 4 β 7 , vedolizumab inhibits the interaction of α 4 β 7 -expressing cells, in particular memory T lymphocytes, with mucosal addressin cell adhesion molecule-1 [MAdCAM-1] on endothelial cells, thereby blocking the infiltration of these cells into the gastrointestinal mucosa and gut-associated lymphoid tissue and suppressing gut inflammation. 1 The efficacy of vedolizumab for achieving clinical response, clinical remission, and mucosal healing [UC only] at Week 6 and clinical remission at Week 52 were demonstrated in patients with UC and patients with CD in the GEMINI 1 and GEMINI 2 studies, respectively. 2, 3 In the GEMINI 3 study, vedolizumab was not more efficacious than placebo in inducing clinical remission at Week 6 but was more efficacious at Week 10 in patients with CD who had previously failed TNFα antagonist therapy. 4 Published data have demonstrated a positive relationship between serum concentrations and efficacy for TNFα antagonists, including infliximab and adalimumab, during induction and maintenance treatment in patients with IBD. [5] [6] [7] [8] [9] [10] Therefore, identification of the factors that influence the clearance and exposure-efficacy relationships of therapeutic antibodies for IBD may assist in optimising dosing regimens to maximise the effectiveness of these drugs in clinical practice.
In a population pharmacokinetic analysis, vedolizumab clearance was similar in patients with either UC or CD. 11 Extreme low albumin concentrations and extreme high body weight values were identified as potentially clinically important predictors of increased clearance. In addition, higher endoscopic subscores were associated with increased clearance in patients with UC. Similar associations have been observed for TNFα antagonists. [12] [13] [14] [15] [16] However, in contrast to TNFα antagonists, coadministration of methotrexate, thiopurines, or aminosalicylates had no effect on vedolizumab clearance in patients with UC or CD. 17, 18 Previously reported post hoc analyses of data from GEMINI 1 and GEMINI 2 suggested that higher trough serum concentrations of vedolizumab were associated with higher rates of clinical remission and clinical response in patients with UC or CD at Week 6 [end of induction]. 2, 3 However, these analyses did not account for potential confounding effects of baseline covariates. Here, we further explore the exposureefficacy relationships for vedolizumab induction therapy, including the potential effects of baseline covariates, in patients with UC or CD in post hoc analyses of data from GEMINI 1, GEMINI 2, and GEMINI 3.
Materials and Methods

GEMINI study design and endpoints
The methods and results of GEMINI 1, GEMINI 2, and GEMINI 3 have been reported in detail previously.
2-4 GEMINI 1 and GEMINI In GEMINI 1, clinical response was defined as a decrease in complete Mayo Clinic score of ≥ 3 points and ≥ 30% decrease from baseline, with a decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point; clinical remission was defined as a complete Mayo Clinic score of ≤ 2 points and no individual subscore > 1 point; and mucosal healing was defined as an endoscopic subscore of ≤ 1 point. In GEMINI 2 and GEMINI 3, clinical remission was defined as a CDAI score of ≤ 150 points; enhanced clinical response was defined as a decrease from baseline in CDAI score of ≥ 100 points; and clinical response was defined as a decrease from baseline in CDAI score of ≥ 70 points.
Vedolizumab serum trough concentrations were measured at Weeks 0, 2 and 4 during the induction phase in GEMINI 1 and GEMINI 2, and at Weeks 6 and 10 in GEMINI 3, using a sandwich enzyme-linked immunosorbent assay. In this assay, a mouse anti-vedolizumab idiotypic antibody was immobilised on microtitre plates. After blocking, serum samples were added to the wells and bound vedolizumab was detected with F[ab′]2 mouse anti-human immunoglobulin G conjugated to horseradish peroxidase, followed by a colourimetric substrate. The lower limit of quantification of the assay was 1.25 ng/ml [0.125 µg/ml in undiluted serum], and the minimum required dilution was 100 [1% serum]. The accuracy of the assay ranged from 2.5% to 10.1% difference, the intra-sample precision ranged from 1.8% to 3.1% coefficient of variation [CV] , and the inter-sample precision ranged from 4.0% to 16.2% CV. 11 Missing C average data for subjects who withdrew early were imputed assuming the subjects remained in the study on their assigned dosing regimen, and missing clinical outcome data were imputed as failure. To evaluate the effects of these covariates on vedolizumab exposure, the exposure-efficacy slopes estimated from the unadjusted and covariate-adjusted models were compared. Model equations and evaluation methods are described in detail in Appendix S1, available as Supplementary data at ECCO-JCC online.
Statistical analysis
Exposure-efficacy relationships for clinical remission and clinical response at Week 6 in patients with UC [GEMINI 1] or CD [GEMINI 2] were depicted by plotting the average model-predicted probability of remission or response against individual predicted cumulative C average for groups defined by quartiles of baseline concentrations of albumin, FC, and CRP, and by previous TNFα antagonist use. The model-predicted probability of remission or response was calculated by holding the exposure fixed and averaging the predicted probability of remission or response over the observed distribution for covariate values among patients in the specified group.
Ethical considerations
The GEMINI study protocols were approved by an investigational review board or independent ethics committee at each study centre. All patients gave written informed consent before study participation.
Results
Study population
Demographics and other baseline characteristics of patients in the GEMINI 1, GEMINI 2, and GEMINI 3 studies have been described in detail previously. [2] [3] [4] Relevant characteristics for patients in each study are summarised in Table S1 , available as Supplementary data at ECCO-JCC online.
Exposure-efficacy relationships in patients with UC
For patients with UC from GEMINI 1, the median vedolizumab trough concentration was higher in remitters than non-remitters at Week 6, with an overlap in concentrations between the two subgroups [ Figure 1A] . Similarly, the median vedolizumab trough concentration was higher in responders than in non-responders at Week 6 [ Figure  S1A , available as Supplementary data at ECCO-JCC online].
Vedolizumab trough concentrations were grouped by quartiles and clinical outcome rates calculated for each quartile. Higher vedolizumab trough concentrations were associated with greater efficacy in patients with UC. Induction trough concentrations less than approximately 17 µg/ml were associated with a clinical remission rate similar to that of placebo [ Figure 2A [> 35.7-140 µg/ml] resulted in an absolute increase in remission rate of approximately 31% [ Figure 2A ]. Higher vedolizumab trough concentrations also were associated with numerically higher rates of clinical response and mucosal healing at Week 6 in patients with UC [ Figure S2A and B, available as Supplementary data at ECCO-JCC online]. Consistent with the quartile analysis, exploratory plots of clinical remission rate at Week 6 against individual predicted cumulative C average revealed an apparent exposure-efficacy relationship in patients with UC. Local regression-smoothed data indicated an increased probability of clinical remission as exposure increased, and this relationship appeared to plateau at higher cumulative C average values [ Figure 3A ]. Similar results were obtained for the analysis of clinical response [ Figure S3A , available as Supplementary data at ECCO-JCC online].
The estimated exposure-efficacy slope [θ 2 ] from the unadjusted regression model for clinical remission was approximately 15% higher than that from the covariate-adjusted model in patients with UC [ Table 1 ]. From the regression analysis, vedolizumab concentration was the strongest factor in predicting clinical remission at Week 6. Within each baseline covariate subgroup, the average probability of clinical remission increased by approximately 15% between vedolizumab cumulative C average values of 35 and 84 µg/ml [5th and 95th percentiles, respectively], whereas the probability of clinical remission increased by approximately 8% to 10% across the range of the covariates tested [comparing the lowest and highest quartile line for each covariate at C average of 84 µg/ml] [ Figure 4A -C]. On average, patients with a higher baseline albumin concentration, lower baseline FC concentration, and no prior TNFα antagonist use had a higher probability of clinical remission, regardless of receiving placebo or vedolizumab. Similar results were obtained for the analysis of clinical response [Table S2 and Figure S4A -C, available as Supplementary data at ECCO-JCC online].
Exposure-efficacy relationships in patients with CD
The median vedolizumab trough concentration was slightly higher in remitters than in non-remitters at Week 6 in patients with CD from GEMINI 2, with a substantial overlap in concentrations between the two subgroups [ Figure 1B] . Similarly, the median vedolizumab concentration was slightly higher in responders than in non-responders at Week 6 [ Figure S1B , available as Supplementary data at ECCO-JCC online].
Analysis of clinical remission rate by vedolizumab trough concentration quartile revealed that higher vedolizumab concentrations were modestly associated with greater efficacy at Week 6 in patients with CD from GEMINI 2. Induction concentrations less than 16 µg/ml were associated with a clinical remission rate similar to that of placebo [ Figure 2B ]. Trough concentration increases from Quartile 1 [≤16.0 µg/ml] to Quartile 4 [> 33.7-177 µg/ml] resulted in an absolute increase in clinical remission rate of approximately 14% [ Figure 2B ]. Higher vedolizumab trough concentrations also were associated with numerically higher rates of clinical response and enhanced clinical response at Week 6 [ Figure S5A and B, available as Supplementary data at ECCO-JCC online].
The exposure-efficacy relationship for clinical remission at Week 6 was shallower in patients with CD from GEMINI 3 than in patients from GEMINI 2. Increasing vedolizumab trough Figure S6A and B, available as Supplementary data at ECCO-JCC online]. However, at Week 10, the absolute rate increase from Quartile 1 to Quartile 4 was approximately 22% for clinical remission [ Figure 2D ] but only 5% or less for either measure of clinical response [ Figure S6C and D, available as Supplementary data at ECCO-JCC online]. Consistent with the quartile analyses, an exploratory plot of clinical remission rate at Week 6 against individual predicted cumulative C average revealed a modest relationship for clinical remission in patients with CD from GEMINI 2. Local regression-smoothed data for clinical remission indicated an increased probability of positive outcome as exposure increased, and this relationship appeared to plateau at higher cumulative C average values [ Figure 3B ]. Similar results were obtained for the analyses of clinical response and enhanced clinical response [ Figure S3B and C, available as Supplementary data at ECCO-JCC online].
The estimated exposure-efficacy slope [θ 2 ] for clinical remission from the unadjusted regression model was approximately 33% higher than that from the covariate-adjusted model [ Table 1 ]. Consistent with the quartile analysis, logistic regression analysis revealed that vedolizumab concentration was a modest factor in predicting remission at Week 6 in patients with CD from GEMINI 2. Within each baseline covariate subgroup, the average probability of clinical remission increased by approximately 10% between cumulative C average values of 32 and 85 µg/ml [5th and 95th percentiles, *P < 0.1; **P < 0.05; ***P < 0.01. 
Discussion
In the post hoc analyses presented herein, we explored the relationships between vedolizumab exposure and clinical outcomes after induction therapy in patients with UC or CD. Previously reported exploratory exposure-efficacy analyses were conducted using the ITT population from GEMINI 1 [UC] and GEMINI 2 [CD] and did not assess the potential effects of confounding baseline factors. 2, 3 Here we extended the analyses to include all treated patients from GEMINI 1 and GEMINI 2 [ie, ITT and non-ITT populations combined] and also those from GEMINI 3 [CD] . In addition, we explored the potential for baseline factors to impact the exposureefficacy relationships at Week 6 in patients from GEMINI 1 and GEMINI 2, using logistic regression.
Consistent with previously published data, 2,3,19 the current analyses revealed a positive relationship between vedolizumab exposure and efficacy in patients with UC or CD. As the overall designs of GEMINI 1 and GEMINI 2 are identical in regard to dose, dose administration times, and pharmacokinetic blood sampling times, the exposure-efficacy relationships in patients with UC or CD from these studies can be directly compared. From the quartile and logistic regression analyses, the exposure-efficacy relationships for vedolizumab at Week 6 appeared steeper in patients with UC than in patients with CD. Several factors may have contributed to this observation, such as differences in disease pathophysiology, the instrument used to measure clinical outcomes, and the time needed to respond to treatment. The CDAI score is a subjective assessment associated with more variability than the Mayo Clinic score, is not an objective measure of inflammation, and may not be sensitive to changes in drug serum concentrations. In addition, available data suggest that more time may be needed to achieve clinical remission with vedolizumab induction therapy in patients with CD. Analyses of data from GEMINI 2 and GEMINI 3 revealed that clinical remission rates were higher at Week 10 than at Week 6, particularly in patients who had previously failed TNFα antagonist therapy. 4, 20 Furthermore, in patients with CD from GEMINI 2 who did not respond to vedolizumab induction therapy at Week 6, continued treatment with vedolizumab led to increases in clinical remission and response rates at Weeks 10, 14, and 52. 21 This is reflected in the European Summary of Product Characteristics, which states that patients with CD who have not responded to vedolizumab therapy by Week 6 may be given an additional dose at Week 10 before being assessed for an induction response at Week 14. 22 Thus, it is possible that the exposure-efficacy relationships might have been steeper in patients with CD from GEMINI 2, had a time point later than Week 6 been evaluated. In support of this hypothesis, quartile analyses revealed a steeper exposure-efficacy relationship for clinical remission at Week 10 than at Week 6 in patients with CD from GEMINI 3.
Interestingly, the exposure-efficacy relationship for clinical remission at Week 6 was shallower in patients with CD from GEMINI 3 than in patients from GEMINI 2. This result may be a reflection of the fact that GEMINI 3 included a higher percentage of patients who had previously failed TNFα antagonist therapy than GEMINI 2 [76% vs 58%]. 3, 4 Such patients may be expected to be more difficult to treat and may need a greater exposure of vedolizumab or more time to achieve remission, as mentioned earlier.
We explored whether baseline factors related to disease severity affected the exposure-efficacy relationships in patients with UC or CD. For both diseases, the unadjusted quartile analysis overestimated the exposure-response relationship. 2, 19 From the logistic regression models, the impact of the baseline covariates tested on the exposure-response relationship for clinical remission was greater in CD than UC [the slope for the unadjusted model was 15% higher in UC and 33% higher in CD than the slope for the adjusted model]. Of the covariates tested, previous TNFα antagonist use was identified as having the greatest impact on clinical outcome rates in both diseases. Patients with UC or CD who were naïve to treatment with TNFα antagonists had an approximately 10% higher probability of achieving clinical remission than patients who had failed previous TNFα antagonist therapy. In patients with CD, the magnitude of this effect was similar to that of vedolizumab concentration. Interestingly, earlier TNFα antagonist use had no clinically relevant effect on vedolizumab linear clearance in the population pharmacokinetic modelling, suggesting that the effects of this factor on efficacy were not related to any effects on vedolizumab pharmacokinetics. 11 Similar effects of earlier TNFα antagonist use on the probability of clinical remission have been reported for adalimumab in patients with UC. 7 The effect of previous TNFα antagonist use on the efficacy of vedolizumab needs further research. The current exposure-efficacy analyses have several limitations. The analyses included data from only one induction dose level of vedolizumab. In addition, patients were randomly assigned to receive a particular dose, not concentration, of vedolizumab, and the analyses were performed retrospectively. Therefore, it is difficult to rule out possible correlation between the pharmacokinetic and clinical outcomes with the available data. Thus, we cannot draw firm conclusions regarding causality or association from the current analyses, and the results should be interpreted with caution.
An additional limitation of the quartile analyses is that they used vedolizumab concentrations measured at one point in time [Week 6 or 10], excluding concentrations measured at other time points. In contrast, the logistic regression analyses used cumulative C average , which was derived from the population pharmacokinetic model and takes into account all serum concentrations measured during the study for a particular individual. The use of cumulative exposures to characterise exposure-efficacy relationships is a more robust analysis, as clinical outcome is affected by exposure over a period of time, not only at a single point in time.
Characterisation of exposure-efficacy relationships may facilitate dose optimisation in patients with predictors of lower exposure and clinical response. An association between trough concentrations and clinical remission, endoscopic improvement, and lower risk of colectomy has been reported for infliximab in patients with UC. 10 In addition, a recent retrospective pooled analysis for infliximab derived cut-off values associated with remission in patients with CD. 5 Furthermore, results from the prospective, controlled TAXIT study showed a causal relationship between drug exposure and efficacy for infliximab in patients with CD. 23 However, this study failed to show additional benefit of the concentration-based dosing over clinically based dosing throughout the first year. Similarly, in the prospective, randomised TAILORIX study, proactive dose intensification based on infliximab trough levels was not superior to dose intensification based on symptoms alone in patients with CD. 24 In view of the above-mentioned limitations of the current vedolizumab analyses, it is not recommended that these analyses be used to identify threshold vedolizumab concentrations associated with efficacy.
In summary, we have further characterised the exposure-efficacy relationships for vedolizumab in patients with UC or CD. Exposureefficacy relationships for clinical remission at the end of induction were steeper in patients with UC than in patients with CD. Of the covariates tested, previous TNFα antagonist use was identified as having the greatest impact on clinical remission rate in both diseases. Patients who were naïve to treatment had a higher probability of a positive outcome. Further research is needed to assess dose individualisation and optimisation in patients receiving vedolizumab in clinical practice.
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